Manager TitleAgeSince
Chief Executive Officer 53 2022-08-29
Director of Finance/CFO 55 2023-05-01
Chief Tech/Sci/R&D Officer 51 -
Director TitleAgeSince
Director/Board Member 53 2015-08-31
Chairman 71 2021-04-14
Director/Board Member 59 2021-04-14
Change 5-day change 1-year change 3-year change Capi.($)
+5.88%+8.00% - - 1.51M
+0.18%-0.07%+1.00%+20.41% 48.63B
+1.89%+5.08%+492.59%+629.24% 46.3B
+1.83%+2.75%+15.61%+91.22% 41.97B
-0.50%-1.56%+24.67%+12.17% 39.51B
-2.74%-7.13%+18.72%+49.04% 31.75B
-1.14%-2.51%+27.52%+136.42% 16.48B
+0.59%-2.25% - - 16.34B
-0.20%-0.11%+2.54%+29.32% 14B
-2.60%-1.00%+77.85%+40.37% 13.33B
Average +0.32%-0.89%+82.56%+126.02% 29.81B
Weighted average by Cap. +0.08%-0.35%+105.59%+155.53%
Logo Amniotics AB
Amniotics AB (publ) is a Sweden-based biotech company that develops cell therapy drugs based on mesenchymal stem cells from amniotic fluid in its in-house GMP licensed facility. Amniotics' own marker technology is used to identify and select stem cells for different tissue types; Lung (PulmoStem), Brain (CogniStem), Kidney (NephroStem), Skin (CutiStem). It allows for selecting the type of cell to be used for specific tissue. The company has developed a process - patented in all steps - which includes collection of amniotic fluid, with a medical device developed by Amniotics, followed by sorting and propagation of stem cells and packaging of product in ampoules in its own GMP facility. Amniotics is a technology and service provider to Universities, Hospitals, and the Biopharmaceutical industry.
Employees
4
  1. Stock Market
  2. Stocks
  3. AMNI Stock